R. M. Sichinava
R. M. Sichinava has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- D. M. Kvitka
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
3 shared publications - O. P. Nechay
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
2 shared publications - Oleksandr A. Tovkai
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
2 shared publications - Volodymyr O. Palamarchuk
Український науково-практичний центр ендокринної хірургії, трансплантацїї ендокринних органів і тканин Міністерства охорони здоров’я України, Київ
2 shared publications - N. I. Belemets
Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
1 shared publication P.O. Lischynskyi
Украинский научно-практический центр эндокринной хирургии, трансплантации эндокринных органов и тканей МЗ Украины, г. Киев, Украина
1 shared publication
Latest Publications
- Open Access
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 25-30
Predictive value of CD138, CD68, CD163 expression in the pathogenesis of the development of thyroid cancer against the background of metabolic disorders
Objective — to investigate the expression of CD138, CD68, CD163, involved in the pathogenesis of papillary thyroid cancer (PTC) against the background of metabolic disorders. Materials and methods. The analysis was performed on 36 selected medical histories of patients who were operated for PTC in the Surgical Department of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the MoH of Ukraine. Patients’ aged ranged 18 to 76 years, the mean age was 41.4 ± 13.8 years; women prevailed among patients — 32. According to the body mass index (BMI) patients were divided into two groups: group 1 (n = 14) with normal weight (BMI < 25 kg/m2), group 2 consisted of 22 overweight patients (BMI ≥ 25 kg/m2). All patients had autoimmune thyroiditis confirmed by laboratory and histological examination. Molecular genetic mutation BRAFV600E was detected in 20 (55.6 %). Immunohistochemical study of markers CD138, CD68, CD163 was performed according to the standard methods on histological material of tumors. Results. Among the studied immunohistochemical markers, CD68 was the most common — 72.2 % of cases, while CD138 and CD138 were found in 50 % and 55.6 %, respectively. In both studied groups, no statistically significant association was found between BMI and the presence of BRAFV600E (p > 0.05). In the immunohistochemical study of markers CD138, CD68 and CD163 no significant relationship between their expression and BMI was found (p > 0.05). Instead, we found a significant difference in the detection of the CD68 marker in patients of both groups (p < 0.01), while CD138 and CD163 did not show significant difference. The aggressiveness of the tumor process occurred in 25 % of patients. Patients in group 1 (with normal BMI) did not have significant differences in the aggressiveness in contrast to patients of the group 2 (21.4 % and 27.3 %, respectively). Conclusions. No increase of the expression of immunohistochemical markers CD138, CD68, CD163, involved in the pathogenesis of PTC, was established in overweight patients; there was no significant correlation between BMI and the presence of BRAFV600E, as well as the aggressiveness of the tumor process.
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 25-30
Open AccessPredictive value of CD138, CD68, CD163 expression in the pathogenesis of the development of thyroid cancer against the background of metabolic disorders
Objective — to investigate the expression of CD138, CD68, CD163, involved in the pathogenesis of papillary thyroid cancer (PTC) against the background of metabolic disorders. Materials and methods. The analysis was performed on 36 selected medical histories of patients who were operated for PTC in the Surgical Department of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the MoH of Ukraine. Patients’ aged ranged 18 to 76 years, the mean age was 41.4 ± 13.8 years; women prevailed among patients — 32. According to the body mass index (BMI) patients were divided into two groups: group 1 (n = 14) with normal weight (BMI < 25 kg/m2), group 2 consisted of 22 overweight patients (BMI ≥ 25 kg/m2). All patients had autoimmune thyroiditis confirmed by laboratory and histological examination. Molecular genetic mutation BRAFV600E was detected in 20 (55.6 %). Immunohistochemical study of markers CD138, CD68, CD163 was performed according to the standard methods on histological material of tumors. Results. Among the studied immunohistochemical markers, CD68 was the most common — 72.2 % of cases, while CD138 and CD138 were found in 50 % and 55.6 %, respectively. In both studied groups, no statistically significant association was found between BMI and the presence of BRAFV600E (p > 0.05). In the immunohistochemical study of markers CD138, CD68 and CD163 no significant relationship between their expression and BMI was found (p > 0.05). Instead, we found a significant difference in the detection of the CD68 marker in patients of both groups (p < 0.01), while CD138 and CD163 did not show significant difference. The aggressiveness of the tumor process occurred in 25 % of patients. Patients in group 1 (with normal BMI) did not have significant differences in the aggressiveness in contrast to patients of the group 2 (21.4 % and 27.3 %, respectively). Conclusions. No increase of the expression of immunohistochemical markers CD138, CD68, CD163, involved in the pathogenesis of PTC, was established in overweight patients; there was no significant correlation between BMI and the presence of BRAFV600E, as well as the aggressiveness of the tumor process.
- Open Access
- 16 December 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 9-18
Calcitonin level in the postoperative period as a risk factor for persistence of medular thyroid cancer
Aim — to evaluate the possibility of using basal calcitonin levels in the postoperative period to assess the effectiveness of surgical treatment of medullary thyroid cancer and the likelihood of its persistence (recurrence). Materials and methods. A single-site retrospective study was conducted to assess results of surgical treatment of 194 patients (74.2 % women and 25.8 % men), from them148 (76.3 %) patients had primary forms of the disease (group 1) and 46 (23.8 %) the recurrent form (group 2). Primary surgery included thyroidectomy, supplemented with thecentral and lateral dissection of the neck. Patients in group 1 were divided into two subgroups depending on the postoperative calcitoninlevels: group 1A with normal calcitonin levels (≤ 18 pg/ml)and group 1B with hypercalcitoninemia (> 18 pg/ml). The quantitativedetermination of blood serum calcitonin levels was performed using automatic immunochemiluminescent analyzer «MAGLUMI» («Snibe Diagnostic», China) in 1 week and 1 year after surgery. Accumulation and primary data processing were performed in MS Excel 2013, statistical processing was performed using StatPlus programs with descriptive statistics, parametric and nonparametric methods for testing statistical hypotheses (Student’s criteria, Mann-Whitney, Fisher angular transformation), analysis of conjugation tables, ROC-analysis. The results were considered statistically significantat p < 0.05. Results. The average duration of follow-up was 67.5 months. The results of surgery were analyzed in terms of absence or presence of clinical recurrence, calcitoninlevels in the early postoperative period (5 days) were used as a predictor. After 2 years of follow-up,normocalcitoninemiawas accompanied by recurrence in almost 2 % of cases, while hypercalcitoninemia — in 61 % to 74 %, depending on the stage and frequency of the disease. The correlationsbetween postoperative calcitonin levels and presence of recurrence (persistence) of medullary thyroid cancer has been established: AUC = 0.928 (0.867; 0.989, Juden index (J) = 0.429, threshold (cut-off point) ≥ 28.1 pg/ml, sensitivity = 0.938 (0.854; 1,000), specificity = 0.855 (0.789; 0.920), predictive value of positive result(PPV) = 0.699, predictive value of negative resultPNV = 0.991. Moreover, countersensitivity scores and incidence of negative test results in patients with relapse depending on the level of postoperative calcitonin were calculated. Conclusions. Postoperative calcitonin levels in 5 days after surgery can be used for assessment of efficacy of the surgical treatment (AUC — 0,928 (0,867; 0,989), Juden index — 0,429)). The prognosis of recurrence-free disease does not depend on the disease stage. At calcitonin levels < 18 pg/ml, clinical signs of the disease persistence (recurrence) were detected in 1.5 % of cases (PNV = 0.991). The reliability of predicting the disease recurrence depended on the stage and frequency of surgery: PRV = 0.612 in primary forms without metastases, PRV = 0.825 in recurrent forms. Calcitonin values < 28.1 pg/ml can be considered a relatively «safe» level.
- 16 December 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 9-18
Open AccessCalcitonin level in the postoperative period as a risk factor for persistence of medular thyroid cancer
Aim — to evaluate the possibility of using basal calcitonin levels in the postoperative period to assess the effectiveness of surgical treatment of medullary thyroid cancer and the likelihood of its persistence (recurrence). Materials and methods. A single-site retrospective study was conducted to assess results of surgical treatment of 194 patients (74.2 % women and 25.8 % men), from them148 (76.3 %) patients had primary forms of the disease (group 1) and 46 (23.8 %) the recurrent form (group 2). Primary surgery included thyroidectomy, supplemented with thecentral and lateral dissection of the neck. Patients in group 1 were divided into two subgroups depending on the postoperative calcitoninlevels: group 1A with normal calcitonin levels (≤ 18 pg/ml)and group 1B with hypercalcitoninemia (> 18 pg/ml). The quantitativedetermination of blood serum calcitonin levels was performed using automatic immunochemiluminescent analyzer «MAGLUMI» («Snibe Diagnostic», China) in 1 week and 1 year after surgery. Accumulation and primary data processing were performed in MS Excel 2013, statistical processing was performed using StatPlus programs with descriptive statistics, parametric and nonparametric methods for testing statistical hypotheses (Student’s criteria, Mann-Whitney, Fisher angular transformation), analysis of conjugation tables, ROC-analysis. The results were considered statistically significantat p < 0.05. Results. The average duration of follow-up was 67.5 months. The results of surgery were analyzed in terms of absence or presence of clinical recurrence, calcitoninlevels in the early postoperative period (5 days) were used as a predictor. After 2 years of follow-up,normocalcitoninemiawas accompanied by recurrence in almost 2 % of cases, while hypercalcitoninemia — in 61 % to 74 %, depending on the stage and frequency of the disease. The correlationsbetween postoperative calcitonin levels and presence of recurrence (persistence) of medullary thyroid cancer has been established: AUC = 0.928 (0.867; 0.989, Juden index (J) = 0.429, threshold (cut-off point) ≥ 28.1 pg/ml, sensitivity = 0.938 (0.854; 1,000), specificity = 0.855 (0.789; 0.920), predictive value of positive result(PPV) = 0.699, predictive value of negative resultPNV = 0.991. Moreover, countersensitivity scores and incidence of negative test results in patients with relapse depending on the level of postoperative calcitonin were calculated. Conclusions. Postoperative calcitonin levels in 5 days after surgery can be used for assessment of efficacy of the surgical treatment (AUC — 0,928 (0,867; 0,989), Juden index — 0,429)). The prognosis of recurrence-free disease does not depend on the disease stage. At calcitonin levels < 18 pg/ml, clinical signs of the disease persistence (recurrence) were detected in 1.5 % of cases (PNV = 0.991). The reliability of predicting the disease recurrence depended on the stage and frequency of surgery: PRV = 0.612 in primary forms without metastases, PRV = 0.825 in recurrent forms. Calcitonin values < 28.1 pg/ml can be considered a relatively «safe» level.
- Open Access
- 30 June 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 70-75
Introduction of the quality of life concept in practical medicine
The modern stage of medical development requires a multidisciplinary approach to studying the impact of treatment on human life. The social aspects are of great importance because the goal of treatment is to preserve or/and improve life. Therefore, the term "quality of life" is increasingly used in the world medical literature. The objectification of this indicator and its adaptation in practical medicine is a priority task. The concept of "quality of life" first appeared in 1958. In the future, this concept was developed in a research carried out by a group of professors at MIT (Massachusetts Institute of Technology) under Prof. R. Bauer in 1966. These researches initiated the quality of life study. In 1996, the WHO developed a definition of quality of life as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. The purpose of studying the quality of life in the medical field was to introduce treatment protocols and standardize medical care. An important criterion for evaluating the quality of treatment was to compare changes in the patient’s quality of life before and after using a particular medical protocol. The main methods of studying changes in the patient’s quality of life were the use of special questionnaires. The most common general-purpose questionnaires for assessing changes in quality of life are SF-36, WHOQoL-100, Sickness Impact Profile, Nottingham Health Profile, EuroQoL-5D, EORTC QLQ-C30. In Ukraine, as of 2020, there is no local questionnaire for either general or specialized purposes. But there are translations of the main questionnaires, for example, SF-36, EORTC QLQ-C30. Developing own questionnaire that fully complies with the standards of the MAPI Research Institute requires multi-center and multidisciplinary research. The study of changes in the quality of life is an integral part of a comprehensive analysis of new methods of the diagnosis, treatment and prevention of diseases. Analysis of changes in the quality of life using different approaches to treatment is possible provided that general and special purpose questionnaires and available clinical data are used. Using advanced statistical processing of the questionnaire survey allows you to increase the reliability of the research. There is a need to develop own specialized adapted nosological questionnaires for quality of life analysis. Assessment of the quality of life should become one of the main criteria for the effectiveness of medical care, as well as an independent indicator of the condition of patients during medical and social expertise, determining the prognosis, treatment tactics, and developing rehabilitation programs.
- 30 June 2021
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 70-75
Open AccessIntroduction of the quality of life concept in practical medicine
The modern stage of medical development requires a multidisciplinary approach to studying the impact of treatment on human life. The social aspects are of great importance because the goal of treatment is to preserve or/and improve life. Therefore, the term "quality of life" is increasingly used in the world medical literature. The objectification of this indicator and its adaptation in practical medicine is a priority task. The concept of "quality of life" first appeared in 1958. In the future, this concept was developed in a research carried out by a group of professors at MIT (Massachusetts Institute of Technology) under Prof. R. Bauer in 1966. These researches initiated the quality of life study. In 1996, the WHO developed a definition of quality of life as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. The purpose of studying the quality of life in the medical field was to introduce treatment protocols and standardize medical care. An important criterion for evaluating the quality of treatment was to compare changes in the patient’s quality of life before and after using a particular medical protocol. The main methods of studying changes in the patient’s quality of life were the use of special questionnaires. The most common general-purpose questionnaires for assessing changes in quality of life are SF-36, WHOQoL-100, Sickness Impact Profile, Nottingham Health Profile, EuroQoL-5D, EORTC QLQ-C30. In Ukraine, as of 2020, there is no local questionnaire for either general or specialized purposes. But there are translations of the main questionnaires, for example, SF-36, EORTC QLQ-C30. Developing own questionnaire that fully complies with the standards of the MAPI Research Institute requires multi-center and multidisciplinary research. The study of changes in the quality of life is an integral part of a comprehensive analysis of new methods of the diagnosis, treatment and prevention of diseases. Analysis of changes in the quality of life using different approaches to treatment is possible provided that general and special purpose questionnaires and available clinical data are used. Using advanced statistical processing of the questionnaire survey allows you to increase the reliability of the research. There is a need to develop own specialized adapted nosological questionnaires for quality of life analysis. Assessment of the quality of life should become one of the main criteria for the effectiveness of medical care, as well as an independent indicator of the condition of patients during medical and social expertise, determining the prognosis, treatment tactics, and developing rehabilitation programs.
- Open Access
- 30 June 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (3) , 272-277
Влияние ожирения на развитие тиреоидного рака: обзор литературы
Избыточная масса тела приводит к ряду хронических заболеваний и влияет на продолжительность жизни. С 1975 по 2016 год распространенность избыточной массы тела у взрослых (индекс массы тела (ИМТ) ≥ 25 кг/м2) увеличилась с почти 21 % у мужчин и 24 % у женщин примерно до 40 % у лиц обоих полов, а распространенность ожирения (ИМТ ≥ 30 кг/м2) увеличилась в четыре раза у мужчин (с 3 до 12 %) и более чем вдвое у женщин (с 7 до 16 %). В 2012 году избыточная масса тела отмечалась приблизительно у 3,9 % от всех пациентов с раковыми заболеваниями (544 300 случаев) и варьировала от менее 1 % в странах с низким уровнем дохода до 8 % в некоторых западных странах с высоким уровнем дохода. На протяжении последних десятилетий наблюдается рост популяции с избыточной массой тела и одновременное увеличение случаев выявления злокачественных новообразований, в том числе тиреоидного рака. Все исследователи сообщают о связи ожирения и рака щитовидной железы и единодушно призывают к дальнейшим исследованиям, которые приведут к пониманию ее основных механизмов. На сегодняшний день возможные механизмы развития оцениваются как сложные и включают многочисленные факторы как на системном, так и на клеточном уровне. Нарушение метаболизма инсулина, адипокины, процессы воспаления и половые гормоны способствуют влиянию ожирения на развитие рака и его прогрессирование. По результатам обзора проведенных исследований можно сделать вывод о существовании связи между избыточной массой тела и повышенным риском развития опухолевого процесса, в том числе развитием рака щитовидной железы. В то же время наличие различных гипотез относительно патофизиологических механизмов и закономерностей связи ожирения и опухолевого процесса с наибольшей вероятностью свидетельствует о мультифакториальнисти данного процесса и побуждает к его дальнейшему углубленному изучению.
- 30 June 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (3) , 272-277
Open AccessВлияние ожирения на развитие тиреоидного рака: обзор литературы
Избыточная масса тела приводит к ряду хронических заболеваний и влияет на продолжительность жизни. С 1975 по 2016 год распространенность избыточной массы тела у взрослых (индекс массы тела (ИМТ) ≥ 25 кг/м2) увеличилась с почти 21 % у мужчин и 24 % у женщин примерно до 40 % у лиц обоих полов, а распространенность ожирения (ИМТ ≥ 30 кг/м2) увеличилась в четыре раза у мужчин (с 3 до 12 %) и более чем вдвое у женщин (с 7 до 16 %). В 2012 году избыточная масса тела отмечалась приблизительно у 3,9 % от всех пациентов с раковыми заболеваниями (544 300 случаев) и варьировала от менее 1 % в странах с низким уровнем дохода до 8 % в некоторых западных странах с высоким уровнем дохода. На протяжении последних десятилетий наблюдается рост популяции с избыточной массой тела и одновременное увеличение случаев выявления злокачественных новообразований, в том числе тиреоидного рака. Все исследователи сообщают о связи ожирения и рака щитовидной железы и единодушно призывают к дальнейшим исследованиям, которые приведут к пониманию ее основных механизмов. На сегодняшний день возможные механизмы развития оцениваются как сложные и включают многочисленные факторы как на системном, так и на клеточном уровне. Нарушение метаболизма инсулина, адипокины, процессы воспаления и половые гормоны способствуют влиянию ожирения на развитие рака и его прогрессирование. По результатам обзора проведенных исследований можно сделать вывод о существовании связи между избыточной массой тела и повышенным риском развития опухолевого процесса, в том числе развитием рака щитовидной железы. В то же время наличие различных гипотез относительно патофизиологических механизмов и закономерностей связи ожирения и опухолевого процесса с наибольшей вероятностью свидетельствует о мультифакториальнисти данного процесса и побуждает к его дальнейшему углубленному изучению.